Abstract

To date, no systematic analyses are available assessing concordance of molecular classifications between primary tumors (PT) and matched liver metastases (LM) of metastatic colorectal cancer (mCRC). We investigated concordance between PT and LM for four clinically relevant CRC gene signatures. Twenty-seven fresh and 55 formalin-fixed paraffin-embedded pairs of PT and synchronous LM of untreated mCRC patients were retrospectively collected and classified according to the MSI-like, BRAF-like, TGFB activated-like and the Consensus Molecular Subtypes (CMS) classification. We investigated classification concordance between PT and LM and association of TGFBa-like and CMS classification with overall survival. Fifty-one successfully profiled matched pairs were used for analyses. PT and matched LM were highly concordant in terms of BRAF-like and MSI-like signatures, (90.2% and 98% concordance, respectively). In contrast, 40% to 70% of PT that were classified as mesenchymal-like, based on the CMS and the TGFBa-like signature, respectively, lost this phenotype in their matched LM (60.8% and 76.5% concordance, respectively). This molecular switch was independent of the microenvironment composition. In addition, the significant change in subtypes was observed also by using methods developed to detect cancer cell-intrinsic subtypes. More importantly, the molecular switch did not influence the survival. PT classified as mesenchymal had worse survival as compared to nonmesenchymal PT (CMS4 vs CMS2, hazard ratio [HR] = 5.2, 95% CI = 1.5-18.5, P = .0048; TGFBa-like vs TGFBi-like, HR = 2.5, 95% CI = 1.1-5.6, P = .028). The same was not true for LM. Our study highlights that the origin of the tissue may have major consequences for precision medicine in mCRC.

Highlights

  • Colorectal cancer (CRC) is one of the most common cancers worldwide, with an estimated 1.2 million cases and over 600 000 deaths per year.[1]

  • primary tumors (PT) classified as mesenchymal had worse survival as compared to nonmesenchymal PT (CMS4 vs consensus molecular subtype 2 (CMS2), hazard ratio [HR] = 5.2, 95% CI = 1.5-18.5, P = .0048; TGFB activated (TGFBa)-like vs TGFB inactivated (TGFBi)-like, HR = 2.5, 95% CI = 1.1-5.6, P = .028)

  • The treatment of metastatic colorectal cancer (mCRC) is based on the molecular profile of the archived primary tissue and this is sufficient in most cases to identify mutations in genes that are predictive of response to conventional biological agents.[3,26]

Read more

Summary

| INTRODUCTION

Colorectal cancer (CRC) is one of the most common cancers worldwide, with an estimated 1.2 million cases and over 600 000 deaths per year.[1]. CRC can be classified into different molecular subtypes based on gene expression patterns.[9,10,11,12,13,14,15] The different molecular subtypes are characterized by the activation of different biological processes, such as microsatellite instability (MSI) and immune infiltration signaling, canonical epithelial signaling activation, metabolic dysregulation and mesenchymal characteristics These subgroups have different prognosis, their predictive value, especially regarding the efficacy of targeted agents, remains under investigation. We investigated if the classification of some tumors, especially the ones classified as belonging to mesenchymal subgroups, could be influenced by the tumor microenvironment Such data could help to understand if the transcriptomic molecular profiling of PT is sufficient to inform treatment choice or if molecular profiling of matching metastases is required to guide clinicians for individualized treatment recommendations in mCRC

| MATERIALS AND METHODS
| RESULTS
Findings
| DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call